About Enterra Medical
Feel the Enterra® Therapy difference
If you’re living with gastroparesis, you know that it can cause pain and discomfort that goes beyond malnutrition or missed meals. It can make you feel like you’re missing out on everything else.
That’s why Enterra Medical was founded: to help people with gastroparesis find the relief to take back their seat at the table.
You’re not alone
In 2022, Enterra Medical was formed to focus exclusively on helping more people find relief through Enterra Therapy—a device originally developed by Medtronic and approved by the FDA in 2000.* While Medtronic continues to be an important partner, Enterra Medical is dedicated to leading the way in therapy innovation and support for people living with gastroparesis.
Unlike diet modifications or surgery, the Enterra System is the first and only device designed to relieve chronic nausea and vomiting symptoms. A small, implantable device that’s customizable and reversible, the Enterra System gently stimulates your stomach, which is designed to help reduce the nausea and vomiting associated with gastroparesis. And over 15,000 people have already received Enterra Therapy.
The journey to relief may not be simple for everyone, but Enterra Medical is here to help you navigate diagnosis, consider the treatment options that are right for you, and find the relief you’ve been searching for.
The information provided on this site is for general educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always talk to your doctor about the best treatment options for your individual situation.
MKT-D-0003, Rev AA
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
*HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?